An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry

Virology

Volumn 352, Issue 2, 2006, Pages 477-484

  Safarian, Diana ^a   Carnec, Xavier ^a   Tsamis, Fotini ^a   Kajumo, Francis ^a,b   Dragic, Tatjana ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

CCR5; Coreceptor; Entry; HIV 1; Inhibitors; Monoclonal antibodies; Small molecules; Synergy; V3 loop

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PA14; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PROTEIN INHIBITOR; RECEPTOR ANTIBODY; SCH C PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS RECEPTOR;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; SENSITIVITY ANALYSIS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS STRAIN;

AMIDES; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; CYCLIC N-OXIDES; DRUG SYNERGISM; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PIPERIDINES; PYRIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747045164     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.05.016     Document Type: Article

References (41)

1. Aarons E.J., Beddows S., Willingham T., Wu L., and Koup R.A. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287 2 (2001) 382-390
2. Abrahamyan L.G., Markosyan R.M., Moore J.P., Cohen F.S., and Melikyan G.B. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J. Virol. 77 10 (2003) 5829-5836
3. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., Hasel K.W., Gauduin M.C., Koup R.A., McDougal J.S., and al. a.e. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11 (1995) 533-539
4. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease [In Process Citation]. Annu. Rev. Immunol. 17 (1999) 657-700
5. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 2 (2000) 627-643
6. Binley J.M., Cayanan C.S., Wiley C., Schulke N., Olson W.C., and Burton D.R. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77 10 (2003) 5678-5684
7. Carrington M., Kissner T., Gerrard B., Ivanov S., O'Brien S.J., and Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am. J. Hum. Genet. 61 6 (1997) 1261-1267
8. Chou T.C., and Rideout D.C. Synergism and Antagonism in Chemotherapy (1991), Academic Press, New York
9. Cormier E.G., and Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76 17 (2002) 8953-8957
10. Cormier E.G., Tran D.N., Yukhayeva L., Olson W.C., and Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75 12 (2001) 5541-5549
11. Dragic T., Trkola A., Lin S.W., Nagashima K.A., Kajumo F., Zhao L., Olson W.C., Wu L., Mackay C.R., Allaway G.P., Sakmar T.P., Moore J.P., and Maddon P.J. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72 1 (1998) 279-285
12. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., and Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 97 10 (2000) 5639-5644
13. Gao F., Morrison S., Robertson D., Thornton C., Craig S., Karlson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., al. e., WHO, Characterization., and N.N. f. I. a. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 70 (1996) 1651-1667
14. Gao F., Robertson D.L., Carruthers C.D., Morrison S.G., Jian B., Chen Y., Barre-Sinoussi F., Girard M., Srinivasan A., Abimiku A.G., Shaw G.M., Sharp P.M., and Hahn B.H. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72 7 (1998) 5680-5698
15. Hartley O., Klasse P.J., Sattentau Q.J., and Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21 2 (2005) 171-189
16. Hwang S.S., Boyle T.J., Lyerly H.K., and Cullen B.R. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 257 5069 (1992) 535-537
17. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., and Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments]. Nat. Med. 4 11 (1998) 1302-1307
18. Kuhmann S.E., Platt E.J., Kozak S.L., and Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74 15 (2000) 7005-7015
19. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., Strizki J.M., Riley J., Baroudy B.M., Wilson I.A., Korber B.T., Wolinsky S.M., and Moore J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78 6 (2004) 2790-2807
20. LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., and Hammer S.M. HIV fusion and its inhibition. Antiviral Res. 50 2 (2001) 95-115
21. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., Berg E., Liu G., Guy H.R., Durell S.R., Parmentier M., Chang C.N., Price K., Tsang M., and Doms R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274 14 (1999) 9617-9626
22. Liu R., Paxton W., Choe S., Ceradini D., Martin S., Horuk R., MacDonald M., Stuhlmann H., Koup R., and Landau N. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-378
23. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., and Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 1 (2005) 182-199
24. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., and Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev., Drug Discov. 3 3 (2004) 215-225
25. Moore J., Sattentau Q., Wyatt R., and Sodroski J. Probing the structure of the surface glycoprotein gp120 of human immunodeficiency virus type 1 with a panel of monoclonal antibodies. J. Virol. 68 (1994) 469-484
26. O'Brien W.A., Koyanagi Y., Namazie A., Zhao J.Q., Diagne A., Idler K., Zack J.A., and Chen I.S. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348 6296 (1990) 69-73
27. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., Segal J.P., Thompson D.A., Kajumo F., Guo Y., Moore J.P., Maddon P.J., and Dragic T. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 5 (1999) 4145-4155
28. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., and Doms R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U.S.A. 99 25 (2002) 16249-16254
29. Reeves J.D., Miamidian J.L., Biscone M.J., Lee F.H., Ahmad N., Pierson T.C., and Doms R.W. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J. Virol. 78 10 (2004) 5476-5485
30. Reynolds C.P., and Maurer B.J. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 110 (2005) 173-183
31. Rodenburg C.M., Li Y., Trask S.A., Chen Y., Decker J., Robertson D.L., Kalish M.L., Shaw G.M., Allen S., Hahn B.H., and Gao F. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res. Hum. Retroviruses 17 2 (2001) 161-168
32. Rusert P., Kuster H., Joos B., Misselwitz B., Gujer C., Leemann C., Fischer M., Stiegler G., Katinger H., Olson W.C., Weber R., Aceto L., Gunthard H.F., and Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79 13 (2005) 8454-8469
33. Seibert C., and Sakmar T.P. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10 17 (2004) 2041-2062
34. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., and Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 22 (2001) 12718-12723
35. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., and Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U.S.A. 99 1 (2002) 395-400
36. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., Moore J.P., Sakmar T.P., and Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77 9 (2003) 5201-5208
37. Vodicka M.A., Goh W.C., Wu L.I., Rogel M.E., Bartz S.R., Schweickart V.L., Raport C.J., and Emerman M. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233 1 (1997) 193-198
38. Weiss C.D. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 5 4 (2003) 214-221
39. Westervelt P., Gendelman H.E., and Ratner L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc. Natl. Acad. Sci. U.S.A. 88 8 (1991) 3097-3101
40. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., and Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 [see comments]. Nature 384 6605 (1996) 179-183
41. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., Chen H., Humblias J., Samson M., Parmentier M., Moore J.P., and Mackay C.R. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 8 (1997) 1373-1381